Paul E. Freiman Profile

Teksia develops memorable events, technology forums and exhibitions through extensive databank of international high-tech communities around the world.

Teksia creates the environment for successful information exchange by linking different communities and their peers to business prospects in the U.S. and international markets.

June 24 - 25

ITF 2009

Stanford University, CA


General Information


Name:	Paul E. Freiman
Company:	Third Age Pharma
Title:
Profile:	Paul E. Freiman is the founder of Third Age Pharma, an advisory company to the biotech industry. He served as President and Chief Executive Officer of Neurobiological Technologies, Inc. (NTI) for 11 years. He is the former Chairman and Chief Executive Officer of Syntex Corporation (Syntex), where he had a long and successful career and was instrumental in the sale of Syntex to Roche Holdings for $5.3 billion. He is credited with much of the marketing success of Syntex's lead product, Naprosyn, and was responsible for moving the product to over-the-counter status, marketed as Aleve. Mr. Freiman currently serves as chairman of the board of Penwest Pharmaceuticals, and also serves on the boards of, NovaBay, Otsuka America Pharmaceuticals, Inc., Otsuka Americas Inc., NeoPharm Inc. and Calypte Biomedical Corporation He has been chairman of the Pharmaceutical Manufacturers of America Association (PhRMA) and has also chaired a number of key PhRMA committees. He served as a member of the Jackson Hole Group, a think tank in the delivery of healthcare. Mr. Freiman holds a B.S. degree in Pharmacy from Fordham University and an honorary doctorate from the Arnold & Marie Schwartz College of Pharmacy.

About ITF | Upcoming Event | Agenda | Speakers | Sponsorship